MX367209B - Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación. - Google Patents

Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación.

Info

Publication number
MX367209B
MX367209B MX2015008709A MX2015008709A MX367209B MX 367209 B MX367209 B MX 367209B MX 2015008709 A MX2015008709 A MX 2015008709A MX 2015008709 A MX2015008709 A MX 2015008709A MX 367209 B MX367209 B MX 367209B
Authority
MX
Mexico
Prior art keywords
combination composition
paracetamol
combined
ibuprofen
composition
Prior art date
Application number
MX2015008709A
Other languages
English (en)
Spanish (es)
Inventor
Campbell Atkinson Hartley
Original Assignee
Aft Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX367209(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aft Pharmaceuticals Ltd filed Critical Aft Pharmaceuticals Ltd
Publication of MX367209B publication Critical patent/MX367209B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2015008709A 2010-11-04 2011-10-26 Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación. MX367209B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ58901110 2010-11-04
PCT/NZ2011/000226 WO2012060719A1 (en) 2010-11-04 2011-10-26 A combination composition

Publications (1)

Publication Number Publication Date
MX367209B true MX367209B (es) 2019-07-22

Family

ID=46024668

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015008709A MX367209B (es) 2010-11-04 2011-10-26 Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación.
MX2013005113A MX2013005113A (es) 2010-11-04 2011-10-26 Una composicion combinada.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013005113A MX2013005113A (es) 2010-11-04 2011-10-26 Una composicion combinada.

Country Status (28)

Country Link
US (6) US20130225685A1 (https=)
EP (1) EP2635269B1 (https=)
JP (2) JP2013541583A (https=)
KR (1) KR101900520B1 (https=)
CN (2) CN107519159A (https=)
AU (1) AU2011324137B2 (https=)
BR (1) BR112013010829B8 (https=)
CA (1) CA2814057C (https=)
CL (1) CL2013001250A1 (https=)
CO (1) CO6771406A2 (https=)
CY (1) CY1123398T1 (https=)
DK (1) DK2635269T3 (https=)
ES (1) ES2742373T3 (https=)
HR (1) HRP20191489T1 (https=)
HU (1) HUE045442T2 (https=)
LT (1) LT2635269T (https=)
MX (2) MX367209B (https=)
MY (1) MY160572A (https=)
NZ (1) NZ609727A (https=)
PH (2) PH12013500689A1 (https=)
PL (1) PL2635269T3 (https=)
PT (1) PT2635269T (https=)
RS (1) RS59258B1 (https=)
RU (2) RU2707089C2 (https=)
SG (1) SG189319A1 (https=)
SI (1) SI2635269T1 (https=)
SM (1) SMT201900481T1 (https=)
WO (1) WO2012060719A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2707089C2 (ru) 2010-11-04 2019-11-22 АФТ Фармасьютикалз Лимитед Комбинированная композиция
US9072710B2 (en) 2012-03-16 2015-07-07 Cumberland Pharmaceuticals Inc. Injectable ibuprofen formulation
WO2016008546A1 (en) * 2014-07-18 2016-01-21 Everbright Pharmaceuticals S.A.R.L. Aqueous formulation comprising paracetamol and ibuprofen
WO2016057389A1 (en) * 2014-10-06 2016-04-14 Cumberland Pharmaceuticals, Inc. Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain
WO2018192664A1 (en) 2017-04-20 2018-10-25 Hyloris Developments Sa METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, COMPRISING ACETAMINOPHEN, AND OPTIONALLY ONE OR MORE NSAIDs, AND A COMPOSITION OBTAINED THEREOF
NZ760633A (en) * 2017-07-10 2025-11-28 Gel Cap Tech Llc Dual release dosage form capsule and methods, devices and systems for making same
US11197830B2 (en) 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
US11568752B2 (en) * 2020-01-28 2023-01-31 David Clark Company Incorporated Gateway retrieval alert device for aircraft pushback operations
WO2023281089A2 (en) 2021-07-08 2023-01-12 Krka, D.D., Novo Mesto Pharmaceutical composition comprising naproxen and paracetamol
GR1010769B (el) * 2023-07-27 2024-09-18 Ιουλια Κλεωνος Τσετη Υδατικο διαλυμα ιβουπροφαινης για χρηση σε ενδοφλεβια χορηγηση
KR20260020463A (ko) 2023-06-02 2026-02-11 이울리아 츠에티 이부프로펜을 포함하는 약학 조성물
GR1010809B (el) * 2023-09-13 2024-10-25 Ιουλια Τσετη Υδατικο διαλυμα ιβουπροφαινης παρακεταμολης για χρηση σε ενδοφλεβια χορηγηση

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020551A1 (en) * 1995-12-05 1997-06-12 Adcock Ingram Limited Pharmaceutical composition comprising a skeletal muscle relaxant, a non-steroidal antiinflammatory agent and an analgesic
JP5185488B2 (ja) * 2001-11-02 2013-04-17 カンバーランド ファーマシューティカルズ,インコーポレーテッド 2−(4−イソブチルフェニル)プロピオン酸の医薬組成物
WO2004093864A1 (en) * 2003-03-21 2004-11-04 Mcneil-Ppc, Inc. Non-steroidal anti-inflammatory drug dosing regimen
MX2007000117A (es) * 2004-07-07 2007-06-15 Aft Pharmaceuticals Ltd Una composicion de combinacion.
KR20060072839A (ko) * 2004-12-23 2006-06-28 김경태 아세트아미노펜과 이부프로펜을 이용하여 통증조절과 해열작용을 하는 주사제
US7934627B2 (en) * 2005-10-13 2011-05-03 Alcoa Inc. Apparatus and method for high pressure extrusion with molten aluminum
ES2651444T3 (es) * 2006-10-20 2018-01-26 Johnson & Johnson Consumer Inc. Combinación de acetaminofeno con ibuprofeno para el tratamiento del dolor
WO2008079818A2 (en) * 2006-12-21 2008-07-03 Soluprin Pharmaceuticals, Inc. Intravenous administration of water soluble analgesic formulations
US20090264530A1 (en) * 2008-04-16 2009-10-22 Nickell Robert P Combined nsaid and acetaminophen formulation and method
JP2012505830A (ja) * 2008-10-14 2012-03-08 エイエフティ ファーマスーティカルズ リミテッド 医薬品及び医薬品治療
AU2010224063B2 (en) * 2009-03-12 2015-04-16 Cumberland Pharmaceuticals Inc Administration of intravenous ibuprofen
AU2011274652B2 (en) * 2010-07-07 2013-08-15 Aft Pharmaceuticals Limited A combination composition comprising ibuprofen and paracetamol
RU2707089C2 (ru) 2010-11-04 2019-11-22 АФТ Фармасьютикалз Лимитед Комбинированная композиция
WO2016057389A1 (en) * 2014-10-06 2016-04-14 Cumberland Pharmaceuticals, Inc. Co-administration of intravenous ibuprofen and acetaminophen for treatment of pain

Also Published As

Publication number Publication date
SG189319A1 (en) 2013-05-31
AU2011324137B2 (en) 2015-05-07
KR20140025314A (ko) 2014-03-04
RS59258B1 (sr) 2019-10-31
SMT201900481T1 (it) 2019-11-13
PH12013500689A1 (en) 2013-05-27
US20230000805A1 (en) 2023-01-05
JP2013541583A (ja) 2013-11-14
JP2017132791A (ja) 2017-08-03
NZ609727A (en) 2015-07-31
BR112013010829B8 (pt) 2022-01-04
SI2635269T1 (sl) 2019-10-30
MY160572A (en) 2017-03-15
RU2015103107A (ru) 2015-06-20
PT2635269T (pt) 2019-09-04
AU2011324137A1 (en) 2013-05-02
US11446266B2 (en) 2022-09-20
US20240207210A1 (en) 2024-06-27
ES2742373T3 (es) 2020-02-14
RU2015103107A3 (https=) 2018-08-20
CO6771406A2 (es) 2013-10-15
US11896567B2 (en) 2024-02-13
CY1123398T1 (el) 2021-10-29
US12220392B2 (en) 2025-02-11
LT2635269T (lt) 2019-09-10
PL2635269T3 (pl) 2019-11-29
EP2635269A4 (en) 2014-09-17
KR101900520B1 (ko) 2018-09-19
CN103298464A (zh) 2013-09-11
JP6353577B2 (ja) 2018-07-04
EP2635269B1 (en) 2019-05-22
HUE045442T2 (hu) 2019-12-30
HRP20191489T1 (hr) 2019-11-15
US20130225685A1 (en) 2013-08-29
US20250134839A1 (en) 2025-05-01
RU2013123646A (ru) 2014-12-10
CL2013001250A1 (es) 2013-08-30
CA2814057C (en) 2022-02-01
MX2013005113A (es) 2013-06-03
CA2814057A1 (en) 2012-05-10
CN107519159A (zh) 2017-12-29
RU2707089C2 (ru) 2019-11-22
US20160235695A1 (en) 2016-08-18
DK2635269T3 (da) 2019-08-26
WO2012060719A1 (en) 2012-05-10
US20190029982A1 (en) 2019-01-31
EP2635269A1 (en) 2013-09-11
PH12021550804A1 (en) 2022-02-14
BR112013010829A2 (pt) 2016-08-16
BR112013010829B1 (pt) 2021-12-21

Similar Documents

Publication Publication Date Title
MX367209B (es) Una composición intravenosa que comprende ibuprofeno y paracetamol en combinación.
EA201290833A1 (ru) Применение амисульприда в качестве противорвотного средства
CA2683786C (en) Use of tapentadol in the treatment of pain and with a reduced incidence of tapentadol-induced side-effects
CO2019000938A2 (es) Moduladores nmda espiro-lactam y métodos de uso de los mismos
MX2015009772A (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CO2018013747A2 (es) Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
AR089509A1 (es) Metodo para tratar la perdida osea alveolar, un implante dental, un anticuerpo antiesclerostina, un gel o matriz que comprende dicho anticuerpo y uso
PE20150161A1 (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple
CL2019000247A1 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos.
NZ715686A (en) Pharmaceutical for oral delivery comprising mgbg and methods of treating disease
PH12022551468A1 (en) Compounds active towards nuclear receptors
CL2012003119A1 (es) Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre.
DOP2010000327A (es) Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona
MY164112A (en) A combination composition comprising ibuprofen and paracetamol
DOP2016000008A (es) Combinación sinergística de paracetamol/celecoxib para el tratamiento de dolor inflamatorio
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.
CL2012003065A1 (es) Combinación farmacéutica que comprende ibuprofeno y l-arginina en una proporción en peso de ibuprofeno/l-arginina entre 1.6 y 5.6, con excepción del valor 1.97; composición farmacéutica sólida que contiene a dicha combinación; y su uso en el tratamiento del dolor, inflamación y/o fiebre.
EA201290378A1 (ru) Композиции, содержащие нестероидные противовоспалительные лекарственные средства
EA201590732A1 (ru) Диспергируемая таблетка
AR061046A1 (es) Mirtazapina para el tratamiento del dolor neuropatico
ZA202102913B (en) Dosage regime
TH152432A (th) องค์ประกอบแบบผสมผสาน
UY32985A (es) Uso de celivarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de celivarona